| 许从峰,韦国栋,牛忠鹏,邢理顺,常 亮,高婷婷.知柏地黄丸治疗对中枢性性早熟女童卵巢容积，卵泡直径及第二性征发育的影响[J].,2022,(19):3772-3775 |
| 知柏地黄丸治疗对中枢性性早熟女童卵巢容积，卵泡直径及第二性征发育的影响 |
| Effect of Zhibai Dihuang Pill on Ovarian Volume, Follicular Diameter and Secondary Sexual Characteristics of Girls with Central Precocious Puberty |
| 投稿时间：2022-03-23 修订日期：2022-04-18 |
| DOI：10.13241/j.cnki.pmb.2022.19.034 |
| 中文关键词: 知柏地黄丸 中枢性性早熟 卵巢容积 卵泡直径 第二性征发育 |
| 英文关键词: Zhibai Dihuang Pill Central precocity Ovarian volume Follicular diameter Secondary sexual characteristics development |
| 基金项目:安徽省自然科学基金项目（1908084QH497） |
|
| 摘要点击次数: 555 |
| 全文下载次数: 398 |
| 中文摘要: |
| 摘要 目的：探究知柏地黄丸治疗对中枢性性早熟（ICPP）女童卵巢容积、卵泡直径及第二性征发育的影响。方法：选取2019年2月~2021年2月于本院就诊的86例ICPP女童，随机分为对照组（n=43）和观察组（n=43），对照组给予醋酸曲普瑞林，观察组在对照组基础上给予知柏地黄丸。比较两组临床疗效、子宫容积、卵巢容积和卵泡直径、性激素水平[促卵泡激素（FSH）、雌二醇（E2）及促黄体激素（LH）]、骨代谢指标水平[Ⅰ型胶原氨基端肽（P1NP）、骨钙素N端中分子片段（N-MID）、Ⅰ型胶原羧基端肽交联（β-CTX）]及不良反应。结果：治疗后与对照组相比，观察组总有效率明显较高（P<0.05），子宫容积、卵巢容积和卵泡直径均明显较小（P<0.05），FSH、E2、LH、P1NP、N-MID及β-CTX水平均明显较低（P<0.05）；两组不良反应总发生率无差异（P>0.05）。结论：知柏地黄丸治疗ICPP患儿具有较好的临床疗效，可减小卵巢、子宫的提前变化，降低性激素水平，改善骨代谢指标水平，安全性较好。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of Zhibai Dihuang Pill on the ovarian volume, follicular diameter and secondary sexual characteristics of ICPP girls. Methods: From February 2019 to February 2021, 86 girls with ICPP treated in our hospital were randomly divided into control group (n=43) and observation group (n=43). The control group was given tripriline acetate, and the observation group was given Zhibaidihuang pill in addition to the control group. Compare two groups clinical curative effect, the volume of uterus, ovarian volume and follicle diameter, sex hormone levels [follicle stimulating hormone (FSH), estradiol (E2) and luteinizing hormone (LH)], bone metabolism index level [Ⅰ type collagen amino peptide (P1NP), osteocalcin in the n-terminal molecular fragment (N-MID), collagen type Ⅰ carboxyl end peptide crosslinking (beta CTX)] Adverse reactions. Results: After treatment, compared with the control group, the total effective rate of observation group was significantly higher (P<0.05), the uterine volume, ovarian volume and follicular diameter were significantly smaller (P<0.05), the levels of FSH, E2, LH, P1NP, N-mid and β-CTX were significantly lower (P<0.05). There was no difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion: Zhibaidihuang pill has good clinical efficacy in the treatment of children with ICPP. It can reduce the advance changes of ovary and uterus, reduce the level of sex hormone, improve the level of bone metabolism index, and has good safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
